Correction: Central Precocious Puberty as the First Sign of Multisystem Involvement

Overview

This correction addresses errors in a case report regarding central precocious puberty linked to KMT2B mutation and STS deletion. Key corrections include reference citations and the reference range for inhibin B.

Background

Central precocious puberty (CPP) can be an early indicator of underlying genetic conditions, such as KMT2B mutations. Accurate reporting of clinical data is essential for understanding these genetic disorders.

Data Highlights

Key Findings

• Central precocious puberty can be a primary manifestation of KMT2B mutations.
• Errors in reference citations can lead to misinterpretation of clinical data.
• The reference range for inhibin B was inaccurately reported and has been corrected.
• Accurate clinical documentation is crucial for understanding genetic disorders.

Clinical Implications

Clinicians should ensure accuracy in clinical documentation to avoid misinterpretation of genetic conditions. Awareness of the potential for CPP as a primary symptom in genetic disorders is important for early diagnosis.

Conclusion

This correction serves to clarify important details in the case report.

Related Resources & Content

1. Feng Y, Yang L, Xu Q-B, Cao L-F, Frontiers in Endocrinology, 2026 -- Central precocious puberty as the initial manifestation of multisystem involvement caused by de novo heterozygous KMT2B mutation and STS hemizygous deletion: a case report
2. Frontiers in Medicine — Case Report: Homozygous KISS1R mutation associated with congenital hypogonadotropic hypogonadism in two siblings: pulsatile GnRH therapy restores pituitary architecture and induces pubertal development
3. The Journal of Clinical Endocrinology & Metabolism — Genetic Factors and Frequency of de novo MEN2 Syndromes
4. Frontiers in Endocrinology — Case Report: rapid progressive puberty in siblings with MC4R p. Arg165Gln: longitudinal follow-up and gonadotropin-releasing hormone agonist treatment
5. Central precocious puberty: an Endocrine Society clinical practice guideline
6. The Effect of Leuprolide Acetate 11.25 mg 3-Month Formulation in Children with Central Precocious Puberty: A Systematic Review and Meta-analysis | Advances in Therapy | Springer Nature Link
7. Central precocious puberty as the initial manifestation of multisystem involvement caused by de novo heterozygous KMT2B mutation and STS hemizygous deletion: a case report - PMC